Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment
10. Januar 2022 06:30 ET
|
Cullinan Oncology, Inc.
Collaboration to identify and advance best-in-class HPK1 protein degraders Exclusive option for Cullinan to license related intellectual property from the collaboration CAMBRIDGE, Mass., Jan. ...
Cullinan Oncology to Present at Upcoming Virtual Investor Conferences
05. Januar 2022 09:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will present at the following virtual healthcare conferences in...
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
04. Januar 2022 07:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted...